E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic spontaneous urticaria |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic spontaneous urticaria |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10072757 |
E.1.2 | Term | Chronic spontaneous urticaria |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the efficacy of rilzabrutinib in study participants with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamines (H1-AH) |
|
E.2.2 | Secondary objectives of the trial |
• To demonstrate the efficacy of rilzabrutinib on urticaria activity composite endpoint and itch or hives, separately, at various time points • To evaluate safety outcome measures • To assess the plasma PK of rilzabrutinib in participants with CSU
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Participants who have a diagnosis of CSU refractory to H1-AH at the time of randomization - Diagnosis of CSU ≥3 months prior to screening visit (Visit 1). - The presence of itch and hives for ≥6 consecutive weeks at any time prior to screening visit (Visit 1) despite the use of H1-AH during this time period. - Participants using a study defined H1-AH for CSU treatment. For participants on stable doses of non-study-approved H1-AH, investigators may switch participants to an equivalent dose of a study-approved H1-AH maintenance medication. - Participants who are omalizumab naïve OR omalizumab-incomplete responders. - Participants must be willing and able to complete a daily symptom ediary for the duration of the study. - During the 7 days before randomization: UAS7 ≥16 and ISS7 ≥8 - Body mass index (BMI) >17.5 and <40 kg/m2. - Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
|
|
E.4 | Principal exclusion criteria |
Participants are excluded from the study if any of the following criteria apply: - Clearly defined underlying etiology for CUs other than CSU (main manifestation being physical urticaria) - Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes. - Participants with active atopic dermatitis (AD). - Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study. - Known or suspected immunodeficiency, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator. - History of serious infections requiring intravenous (IV) therapy with the potential for recurrence (as judged by the Site Investigator) with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher), including active coronavirus disease 2019 (COVID-19) - Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening. - Active malignancy or history of malignancy within 5 years - Conditions that may predispose the participant to excessive bleeding - Any participant with an uncontrolled disease state as judged by the Investigator, such as asthma, psoriasis, or inflammatory bowel disease, etc. that are typically treated with oral or parenteral corticosteroids - Previous use of a BTK inhibitor. - Has received any investigational drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer). - Previous exposure to another investigative drug for CSU - Positive for human immunodeficiency virus (HIV) antibody test. - Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with positive DNA test result at screening or within 3 months prior to the screening visit. - Positive hepatitis C antibody test result at screening or within 3 months prior to the screening visit. - Tuberculosis infection - Any of significant laboratory abnormalities and ECG findings at the screening visit |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1 - Change from baseline in weekly urticaria activity score (UAS7) at Week 12 (except US and US reference countries) 2 - For US and US reference countries only: change from baseline in weekly itch severity score (ISS7) at Week 12 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1, 2 - From baseline to Week 12 |
|
E.5.2 | Secondary end point(s) |
1 - Change from baseline in UAS7 at Week 4 2 - Change from baseline in ISS7 at Week 12 (except US and US reference countries) 3 - For US and US reference countries only: change from baseline in UAS7 at Week 12 4 - Change from baseline in weekly hives severity score (HSS7) at Week 12 5 - Proportion of participants with UAS7 ≤6 at Week 12 6 - Proportion of participants with UAS7 = 0 at Week 12 7 - Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and withdrawals due to TEAEs during the double-blind period and the open label extension 8 - Plasma PK concentrations of rilzabrutinib in participants with CSU |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 - From baseline to Week 4 2, 3, 4 - From baseline to Week 12 5, 6 - At Week 12 7,8 - Until Week 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Taiwan |
Canada |
Japan |
Korea, Republic of |
Russian Federation |
Germany |
Italy |
Poland |
Spain |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |